Ricerca avanzata

Home > Riviste > The Quarterly Journal of Nuclear Medicine and Molecular Imaging > Fascicoli precedenti > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2016 Dicembre;60(4) > The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2016 Dicembre;60(4):354-61

FASCICOLI E ARTICOLI   I PIÙ LETTI   eTOC

ULTIMO FASCICOLOTHE QUARTERLY JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Rivista di Medicina Nucleare e Imaging Molecolare


A Journal on Nuclear Medicine and Molecular Imaging
Affiliated to the Society of Radiopharmaceutical Sciences and to the International Research Group of Immunoscintigraphy
Indexed/Abstracted in: Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index (SciSearch), Scopus
Impact Factor 2,413

 

The Quarterly Journal of Nuclear Medicine and Molecular Imaging 2016 Dicembre;60(4):354-61

AN UPDATE ON NUCLEAR CARDIOLOGY 

 REVIEWS

Positron-emission tomography myocardial blood flow quantification in hypertrophic cardiomyopathy

Roberto SCIAGRÀ

Nuclear Medicine Unit, Department of Experimental and Clinical Biomedical Sciences, University of Florence, Florence, Italy

In the setting of hypertrophic cardiomyopathy (HCM), ischemia plays a possibly under-evaluated role. In particular, a large body of evidence indicates that structural and functional abnormalities in the coronary microcirculation contribute to myocardial ischemia and are key elements for HCM pathophysiology and clinical evolution. Measurement of myocardial blood flow (MBF) at rest and under maximal hyperemia (hMBF) by means of perfusion positron-emission tomography (PET) is the most effective way to assess microvascular dysfunction in humans. Therefore, hMBF abnormalities reflect HCM severity and correlate with other important features, such as ischemic symptoms and myocardial fibrosis. Most importantly, it has been demonstrated that severely blunted hMBF implies an adverse outcome in HCM patients. Therefore, PET could be helpful for stratifying patient prognosis and should be used in selected patient subsets to identify those at risk of unfavorable evolution.

lingua: Inglese


FULL TEXT  ESTRATTI

inizio pagina